A Safety Study of Orally Administered BPM31510 in Healthy Subjects

Summary

This is an open-label, Phase I study of the bioavailability and safety of BPM31510 in healthy subjects dosed 2 or 3 times daily for 4 days, after an initial cohort of 6 subjects receiving a single dose (pre-study cohort). The pre-study cohort subjects will receive 1600 mg as a single administration. Cohort 1 and Cohort 2 will consist of 10 patients each. The cohorts may be enrolled sequentially.

Timeline

Start

2015-11

Primary completion

2016-01

Completion

2016-01

Drugs

Indications

No indication recorded.